225Ac-SSO110 has received U.S. FDA Orphan Drug Designation Initial safety data from SANTANA-225 in ES-SCLC and MCC expected in 2026 Potential to address a broad range of neuroendocrine cancers Nov. 11, 2025 -- Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in cancer care, today announced that the first patient has been dosed in the SANTANA-225 Phase 1/2 study of 225Ac-SSO110 for the treatment of extensive stage small cell lung cancer (ES

Nov. 11, 2025 -- Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS (amyotrophic lateral sclerosis). In a newly published study, its researchers found that a drug already approved to treat cancer—called venetoclax—was able to prevent the progression of ALS in 100% of treated mice that would otherwise develop and die from the disease. The study showed that mice treated with venetoclax maintained their abili

Nov. 10, 2025 -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced that it has entered into a securities purchase agreement with Hexstone Capital LLC ("Hexstone"), a family office that has invested in a significant number of Digital Asset Treasury (DAT) companies across a range of digital assets including BTC, ETH, SOL, DOGE, ATH, OG, and INJ. The

Rosnilimab was safe and well tolerated with similar adverse event rates vs. placebo Observed expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy at Week 12 does not support further development of rosnilimab in UC and trial will be discontinued, resulting in at least $10 million in savings Will provide update in H1 2026 on advancement of rosnilimab in RA, which would be funded by strategic or other sources of capital without diluting our royalt

Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash position, which is expected to fund Biofrontera to profitability. Proceeds will support the growth of Biofrontera’s commercial photodynamic therapy (PDT) platform, and expansion of Ameluz® into additional indications. Nov. 07, 2025 -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera”

-RIDE-001, a first-in-class nanomedicine, effectively trained myeloid progenitor cells to elicit myeloid-driven anticancer innate immune responses, as demonstrated in preclinical studies across multiple species Nov. 07, 2025 -- Trained Therapeutix, Inc., a biotech company training immunity at its origin with nanomedicines, today announced preclinical data on RIDE-001, a nanomedicine designed to program myeloid progenitor cells for an anticancer innate immune response, were presented in a poste

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion, and nasal polyps in patients aged 6 years and older compared to placebo Dupixent sBLA accepted for priority review by the US FDA with a target ac

— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy, and in combination with anti-PD-1 antibody, was manageable and consistent with conditional binding of the AXL target restricted to the tumor microenvironment Nov. 07, 2025 -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology com

-- Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established scalable manufacturing --TK-6302 Clinical Trial Application planned in Q4 2025 for initiation of the Phase 1 ATLAS trial in 2026 Nov. 07, 2025 -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced multiple presentations on TK-6302 were featured at the Society for

-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum -89%), a mean reduction in triglycerides (TG) of -55% (maximum -84%), and a mean reduction of low-density lipoprotein (LDL) of -49% (maximum -87%) at the highest dose- -Among participants with elevated baseline TG (>150 mg/dL)